Aberrant PM marker expression in AML post–cycle 2 predicts risk of relapse. (A) Relapse-free survival of patients positive (PM⁺, red) or negative (PM^–, blue) for one or more PM markers at diagnosis and at the MRD measurement (n = 72). (B) Multivariate risk analysis. No LAIP indicates that an LAIP could not be determined at diagnosis. Molecular MRD is defined as presence of NPM1cyt or FLT3-ITD; patients that were wild type for these mutations at diagnosis were not included. A P value based on a Wald test of P < .05 was considered significant. (C) Relapse-free survival of EF^– PM^–, EF⁺ PM^–, EF^– PM⁺, and EF⁺ PM⁺ patients. EF, EuroFlow; CI, confidence interval; HR, hazard ratio; HSCT, hematopoietic stem cell transplantation; WBC, white blood cell.